These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24137339)

  • 1. A GWAS-identified susceptibility locus on chromosome 11q13.3 and its putative molecular target for prediction of postoperative prognosis of human renal cell carcinoma.
    Su T; Han Y; Yu Y; Tan X; Li X; Hou J; DU Y; Shen J; Wang G; Ma L; Jiang S; Zhang H; Cao G
    Oncol Lett; 2013 Aug; 6(2):421-426. PubMed ID: 24137339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population.
    Cao Q; Qin C; Ju X; Meng X; Wang M; Zhu J; Li P; Chen J; Zhang Z; Yin C
    Mutagenesis; 2012 May; 27(3):345-50. PubMed ID: 22131124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genome-wide association study of renal cell carcinoma among African Americans.
    Purdue MP; Ye Y; Wang Z; Colt JS; Schwartz KL; Davis FG; Rothman N; Chow WH; Wu X; Chanock SJ
    Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):209-14. PubMed ID: 24220910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma.
    Ma R; Liu C; Lu M; Yuan X; Cheng G; Kong F; Lu J; Strååt K; Björkholm M; Ma L; Xu D
    Urol Oncol; 2019 May; 37(5):301.e1-301.e10. PubMed ID: 30738744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.
    Purdue MP; Johansson M; Zelenika D; Toro JR; Scelo G; Moore LE; Prokhortchouk E; Wu X; Kiemeney LA; Gaborieau V; Jacobs KB; Chow WH; Zaridze D; Matveev V; Lubinski J; Trubicka J; Szeszenia-Dabrowska N; Lissowska J; Rudnai P; Fabianova E; Bucur A; Bencko V; Foretova L; Janout V; Boffetta P; Colt JS; Davis FG; Schwartz KL; Banks RE; Selby PJ; Harnden P; Berg CD; Hsing AW; Grubb RL; Boeing H; Vineis P; Clavel-Chapelon F; Palli D; Tumino R; Krogh V; Panico S; Duell EJ; Quirós JR; Sanchez MJ; Navarro C; Ardanaz E; Dorronsoro M; Khaw KT; Allen NE; Bueno-de-Mesquita HB; Peeters PH; Trichopoulos D; Linseisen J; Ljungberg B; Overvad K; Tjønneland A; Romieu I; Riboli E; Mukeria A; Shangina O; Stevens VL; Thun MJ; Diver WR; Gapstur SM; Pharoah PD; Easton DF; Albanes D; Weinstein SJ; Virtamo J; Vatten L; Hveem K; Njølstad I; Tell GS; Stoltenberg C; Kumar R; Koppova K; Cussenot O; Benhamou S; Oosterwijk E; Vermeulen SH; Aben KK; van der Marel SL; Ye Y; Wood CG; Pu X; Mazur AM; Boulygina ES; Chekanov NN; Foglio M; Lechner D; Gut I; Heath S; Blanche H; Hutchinson A; Thomas G; Wang Z; Yeager M; Fraumeni JF; Skryabin KG; McKay JD; Rothman N; Chanock SJ; Lathrop M; Brennan P
    Nat Genet; 2011 Jan; 43(1):60-5. PubMed ID: 21131975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma.
    Xing Q; Li R; Xu A; Qin Z; Tang J; Zhang L; Tang M; Han P; Wang W; Qin C; Du M; Zhang W
    Cancer Med; 2019 Jun; 8(6):2886-2896. PubMed ID: 31038847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Cyclin D1 Expression in Renal Cell Carcinoma: a Systematic Review and Meta-analysis.
    Li Z; Liu J; Zhang X; Fang L; Zhang C; Zhang Z; Yan L; Tang Y; Fan Y
    Pathol Oncol Res; 2020 Jul; 26(3):1401-1409. PubMed ID: 31748879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population.
    Xue J; Qin Z; Li X; Zhang J; Zheng Y; Xu W; Cao Q; Wang Z
    Oncotarget; 2017 Oct; 8(46):80889-80899. PubMed ID: 29113352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of cyclin D1 in renal cell carcinoma.
    Lima MS; Pereira RA; Costa RS; Tucci S; Dantas M; Muglia VF; Ravinal RC; Barros-Silva GE
    Int Urol Nephrol; 2014 May; 46(5):905-13. PubMed ID: 24242739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression.
    Liu Y; Han X; Yu Y; Ding Y; Ni C; Liu W; Hou X; Li Z; Hou J; Shen D; Yin J; Zhang H; Thompson TC; Tan X; Cao G
    Sci Rep; 2016 May; 6():26689. PubMed ID: 27225192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma.
    Plath M; Broglie MA; Förbs D; Stoeckli SJ; Jochum W
    J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):53. PubMed ID: 30189895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx.
    Rydzanicz M; Golusinski P; Mielcarek-Kuchta D; Golusinski W; Szyfter K
    Eur Arch Otorhinolaryngol; 2006 Jan; 263(1):43-8. PubMed ID: 16258756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression.
    Tan X; Wang Y; Han Y; Chang W; Su T; Hou J; Xu D; Yu Y; Ma W; Thompson TC; Cao G
    Br J Cancer; 2013 Dec; 109(12):3105-15. PubMed ID: 24157827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
    Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
    BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-D1 expression in human renal-cell carcinoma.
    Hedberg Y; Davoodi E; Roos G; Ljungberg B; Landberg G
    Int J Cancer; 1999 Jun; 84(3):268-72. PubMed ID: 10371345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variations in MAGE-A11 predict the risk and survival of renal cell cancer.
    Su S; Gu Q; Xu A; Shen S; Liu S; Zhang C; Miao C; Qin C; Liu B; Wang Z
    J Cancer; 2019; 10(20):4860-4865. PubMed ID: 31598157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations in microRNAs and the risk and survival of renal cell cancer.
    Du M; Lu D; Wang Q; Chu H; Tong N; Pan X; Qin C; Yin C; Wang M; Zhang Z
    Carcinogenesis; 2014 Jul; 35(7):1629-35. PubMed ID: 24681820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.